ADAMTS12

Across TCGA pan-cancer cohorts, ADAMTS12 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ADAMTS12 data layer compared with 24 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADAMTS12 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ADAMTS12 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where ADAMTS12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.434	0.702	.005	34	view →
LSCC	DFS	Quartile	All	0.204	0.890	.006	17	view →
LUAD	DFS	Quartile	II,III,IV	0.996	0.772	.029	4	view →
HNSC	DFS	Median	III,IV	1.000	0.880	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ADAMTS12–PDAC (OS)

Open the PDAC breakdown →